Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
StemRIM (4599.T)
Ibaraki, JP
StemRIM is a biotechnology firm dedicated to developing regenerative medicines aimed at treating severe and challenging diseases. Its product pipeline includes PJ1, a regeneration-inducing medicine based on HMGB1 peptides, which is currently undergoing Phase II clinical trials for a range of conditions such as epidermolysis bullosa, cerebral infarction, osteoarthritis, chronic liver disease, and cardiomyopathy. Beyond PJ1, StemRIM is also advancing PJ2, another regeneration-inducing medicine utilizing novel peptides A and B; PJ3, a biologic protein designed to promote regeneration; PJ4, a device for collecting a patient's own cells for therapeutic purposes; and PJ5, a stem cell-based gene therapy. Established in 2006, StemRIM is headquartered in Ibaraki, Japan.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +4.93% | +7.97% | -2.93% | -2.30% | +17.79% | +12.45% | -16.06% | -70.47% | -61.79% | -68.66% | -68.66% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-06 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%+5.5% Q2'26: -13.1% (vs Q2'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%-616.8% Q2'26: -468.2% (vs Q2'25)
-
Share dilution Biotechnology: -3.4%+1.0% ★ Q2'26: +0.9% (vs Q2'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.00× Q2'26: 0.00× (vs Q2'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Jul 2019 actual |
Jul 2020 actual |
Jul 2021 actual |
Jul 2022 actual |
Jul 2023 actual |
Jul 2024 actual |
Jul 2025 actual |
Jul 2026 1 Rev. Ana. 1 EPS Ana. |
Jul 2027 1 Rev. Ana. 1 EPS Ana. |
Jul 2028 1 Rev. Ana. 1 EPS Ana. |
Jul 2029 1 Rev. Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
100.00M
est: 100.00M (+0.0%)
|
2.10B
est: 1.53B (+37.0%)
|
1.40B
est: 1.40B (+0.0%)
|
22.98M
est: 100.00M (-77.0%)
|
2.35B
est: 2.35B (+0.0%)
|
—
est: 1.00B (-100.0%)
|
—
est: 1.00B (-100.0%)
|
540.00M
540.00M – 540.00M
-46.0% YoY
|
540.00M
540.00M – 540.00M
+0.0% YoY
|
541.00M
541.00M – 541.00M
+0.2% YoY
|
1.15B
1.15B – 1.15B
+111.6% YoY
|
| EBITDA |
-725.20M
est: 14.25M (-5,188.2%)
|
423.44M
est: 218.54M (+93.8%)
|
-550.13M
est: 199.53M (-375.7%)
|
-1.93B
est: 14.25M (-13,650.0%)
|
190.18M
est: 334.93M (-43.2%)
|
-2.03B
est: 137.59M (-1,576.6%)
|
-1.92B
est: 137.59M (-1,496.9%)
|
74.30M
74.30M – 74.30M
-46.0% YoY
|
74.30M
74.30M – 74.30M
+0.0% YoY
|
74.44M
74.44M – 74.44M
+0.2% YoY
|
157.55M
157.55M – 157.55M
+111.6% YoY
|
| EBIT |
-726.86M
est: 13.22M (-5,596.9%)
|
415.71M
est: 202.75M (+105.0%)
|
-593.73M
est: 185.12M (-420.7%)
|
-1.98B
est: 13.22M (-15,079.1%)
|
142.39M
est: 310.74M (-54.2%)
|
-2.08B
est: 127.30M (-1,730.9%)
|
-1.97B
est: 127.30M (-1,648.7%)
|
68.74M
68.74M – 68.74M
-46.0% YoY
|
68.74M
68.74M – 68.74M
+0.0% YoY
|
68.87M
68.87M – 68.87M
+0.2% YoY
|
145.76M
145.76M – 145.76M
+111.6% YoY
|
| Net Income |
-721.21M
est: -1.02B (+29.4%)
|
347.76M
est: -185.74M (+287.2%)
|
-582.45M
est: -684.16M (+14.9%)
|
-1.95B
est: -1.89B (-3.2%)
|
168.35M
est: 253.85M (-33.7%)
|
-2.02B
est: -2.12B (+4.5%)
|
-1.93B
est: -1.01B (-91.2%)
|
-1.91B
-1.91B – -1.91B
-89.0% YoY
|
-1.41B
-1.41B – -1.41B
+26.0% YoY
|
-1.46B
-1.46B – -1.46B
-3.5% YoY
|
—
— – —
+100.0% YoY
|
| SGA |
185.46M
est: 558.37M (-66.8%)
|
320.34M
est: 8.56B (-96.3%)
|
436.05M
est: 7.82B (-94.4%)
|
549.24M
est: 558.37M (-1.6%)
|
608.90M
est: 13.12B (-95.4%)
|
594.09M
est: 5.30B (-88.8%)
|
547.85M
est: 5.30B (-89.7%)
|
2.86B
2.86B – 2.86B
-46.0% YoY
|
2.86B
2.86B – 2.86B
+0.0% YoY
|
2.86B
2.86B – 2.86B
+0.2% YoY
|
6.06B
6.06B – 6.06B
+111.6% YoY
|
| EPS |
-13.77
est: -16.50 (+16.5%)
|
6.44
est: -3.00 (+314.7%)
|
-10.02
est: -11.05 (+9.3%)
|
-32.92
est: -30.50 (-7.9%)
|
2.80
est: 4.10 (-31.7%)
|
-32.98
est: -34.20 (+3.6%)
|
-31.16
est: -16.30 (-91.2%)
|
-30.80
-30.80 – -30.80
-89.0% YoY
|
-22.80
-22.80 – -22.80
+26.0% YoY
|
-23.60
-23.60 – -23.60
-3.5% YoY
|
—
— – —
+100.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-06-16 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-06-15 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-06-12 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-06-11 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-06-10 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-06-09 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-06-08 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-06-05 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-06-04 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-06-03 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-06-02 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-06-01 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-29 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-28 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-27 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-26 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-25 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-22 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-21 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-20 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-19 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-18 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-15 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-14 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-13 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-12 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-11 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-08 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-07 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-01 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-30 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-28 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-27 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-24 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-23 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-22 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-21 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-20 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-17 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-16 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-15 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares International Small-Cap Equity Factor ETF ISCF | 0.01% | 84.9K | 0.24% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Masatsune Okajima | President, Chief Executive Officer & Representative Director | 30M | male |
| Katsuto Tamai | Founder, Chief Scientific Officer & Director | — | male |
| Takehiko Yamazaki | Executive Officer, Head of Seeds Exploration Dept., Pharma. Research Dept. & Intellectual Property Dept. | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 4599.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
